Antibody to S100a6 protein is a sensitive immunohistochemical marker for neurothekeoma
dc.contributor.author | Fullen, Douglas R. | en_US |
dc.contributor.author | Lowe, Lori | en_US |
dc.contributor.author | Su, Lyndon D. | en_US |
dc.date.accessioned | 2010-06-01T21:30:33Z | |
dc.date.available | 2010-06-01T21:30:33Z | |
dc.date.issued | 2003-02 | en_US |
dc.identifier.citation | Fullen, Douglas R.; Lowe, Lori; Su, Lyndon D. (2003). "Antibody to S100a6 protein is a sensitive immunohistochemical marker for neurothekeoma." Journal of Cutaneous Pathology 30(2): 118-122. <http://hdl.handle.net/2027.42/74565> | en_US |
dc.identifier.issn | 0303-6987 | en_US |
dc.identifier.issn | 1600-0560 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/74565 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12641790&dopt=citation | en_US |
dc.description.abstract | Neurothekeoma is a benign tumor of putative peripheral nerve sheath origin. It occurs in a myxoid (classic) variant, cellular variant, and intermediate (mixed) variant. Cellular neurothekeoma (CNT) usually involves the head and neck or extremities of young patients. Histologically, CNT can be confused with melanocytic and fibrohistiocytic lesions. An immunohistochemical antibody panel is often necessary to confirm the histological impression and exclude melanocytic and/or fibrohistiocytic lesions. Methods: Formalin-fixed, paraffin-embedded archival tissues were evaluated by immunohistochemistry using antibodies specific for S100A6 and PGP9.5 in 11 cases of neurothekeoma (seven cellular, four myxoid). A variety of other antibodies were evaluated by immunohistochemistry at the time of initial diagnosis. Results: All 11 neurothekeoma cases were positive for S100A6 protein (four cases, weak/1+ ; seven cases, strong/2+), corresponding to 100% sensitivity. In contrast, eight of 11 neurothekeoma cases (73% sensitivity) were positive for PGP9.5. All seven CNT cases were negative for S100B, as expected. Conclusions: Anti-S100A6 is a highly sensitive antibody for neurothekeomas, including CNT, and, in our experience, is superior in sensitivity to PGP9.5. However, like other antibodies used in evaluating neurothekeomas, S100A6 lacks specificity, as has been demonstrated in previous studies. Nevertheless, S100A6 can be useful in an immunohistochemical antibody panel to evaluate lesions where the differential diagnosis includes CNT. Fullen DR, Lowe L, Su LD. Antibody to S100a6 protein is a sensitive immunohistochemical marker for neurothekeoma. | en_US |
dc.format.extent | 6646805 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Munksgaard International Publishers | en_US |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | © Munksgaard 2002 | en_US |
dc.title | Antibody to S100a6 protein is a sensitive immunohistochemical marker for neurothekeoma | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Dermatology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Departments of Pathology and Dermatology, University of Michigan Hospitals, Ann Arbor, Michigan, MI, USA | en_US |
dc.identifier.pmid | 12641790 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/74565/1/j.1600-0560.2002.00032.x.pdf | |
dc.identifier.doi | 10.1034/j.1600-0560.2002.00032.x | en_US |
dc.identifier.source | Journal of Cutaneous Pathology | en_US |
dc.identifier.citedreference | Gallager RL, Helwig EB. Neurothekeoma – A benign cutaneous tumor of neural origin. Am J Clin Path 1980; 74: 759. | en_US |
dc.identifier.citedreference | Harkin JC, Reed RJ. Tumors of the peripheral nervous system. In: Rosai J, Sobin LH (eds). Fascicle 3, 2nd edn. Washington DC: Armed Forces Institute of Pathology, 1969; 60. | en_US |
dc.identifier.citedreference | Rosati LA, Fratamico FCM, Eusebi V. Cellular neurothekeoma. Appl Pathol 1986; 4: 186. | en_US |
dc.identifier.citedreference | Argenyi ZB, LeBoit PE, Santa Cruz D, Swanson PE, Kutzner H. Nerve sheath myxoma (neurothekeoma) of the skin: light microscopic and immunohistochemical reappraisal of the cellular variant. J Cutan Pathol 1993; 20: 294. | en_US |
dc.identifier.citedreference | Barnhill RL, Mihm MC. Cellular neurothekeoma: a distinctive variant of neurothekeoma mimicking nevomelanocytic tumors. Am J Surg Pathol 1990; 14: 113. | en_US |
dc.identifier.citedreference | Calonje E, Wilson-Jones E, Smith NP, Fletcher CDM. Cellular ‘neurothekeoma’: an epithelioid variant of pilar leiomyoma? Morphological and immunohistochemical analysis of a series. Histopathology 1992; 20: 397. | en_US |
dc.identifier.citedreference | Husain S, Silvers DN, Halperin AJ, McNutt NS. Histologic spectrum of neurothekeoma and the value of immunoperoxidase staining for S100 protein in distinguishing it from melanoma. Am J Dermatopathol 1994; 16: 496. | en_US |
dc.identifier.citedreference | Zelger BG, Steiner H, Kutzner H, Maier H, Zelger B. Cellular ‘neurothekeoma’: An epithelioid variant of dermatofibroma? Histopathology 1998; 32: 414. | en_US |
dc.identifier.citedreference | Busam KJ, Mentzel T, Colpaert C, Barnhill RL, Fletcher CDM. Atypical or worrisome features in cellular neurothekeoma. A study of 10 cases. Am J Surg Pathol 1998; 22: 1067. | en_US |
dc.identifier.citedreference | Argenyi ZB, Kutzner H, Seaba MM. Ultrastructural spectrum of cutaneous nerve sheath myxoma/cellular neurothekeoma. J Cutan Pathol 1995; 22: 137. | en_US |
dc.identifier.citedreference | Barnhill RL, Dickersin GR, Nickeleit V et al. Studies on the cellular origin of neurothekeoma: Clinical, light microscopic, immunohistochemical, and ultrastructural observations. J Am Acad Dermatol 1991; 25: 80. | en_US |
dc.identifier.citedreference | Tomasini C, Aloi F, Pippione M. Cellular neurothekeoma. Dermatology 1996; 192: 160. | en_US |
dc.identifier.citedreference | Wang AR, May D, Bourne P, Scott G. PGP. 9.5: a marker for cellular neurothekeoma. Am J Surg Pathol 1999; 23: 1401. | en_US |
dc.identifier.citedreference | BÖni R, Burg G, Doguoglu A et al. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions. Br J Dermatol 1997; 137: 39. | en_US |
dc.identifier.citedreference | Kuźnicki J, Filipek A, Heimann P, Kaczmarek L, Kamińska B. Tissue-specific distribution of calcyclin 10.5 kDa Ca2+-binding protein. FEBS Lett 1989; 254: 141. | en_US |
dc.identifier.citedreference | Tonini GP, Casalaro A, Cara A, DiMartino D. Inducible expression of calcyclin, a gene with strong homology to S-100 protein, during neuroblastoma cell differentiation and its prevalent expression in Schwann-like cells. Cancer Res 1991; 51: 1733. | en_US |
dc.identifier.citedreference | Fullen DR, Reed JA, Finnerty B, McNutt NS. S100A6 preferentially labels type C nevus cells and nevic corpuscles: Additional support for Schwannian differentiation of intradermal nevi. J Cutan Pathol 2001; 28: 393. | en_US |
dc.identifier.citedreference | Mackie RM, Campbell I, Turbitt ML. Use of NK1 C3 monoclonal antibody in the assessment of benign and malignant melanocytic lesions. J Clin Pathol 1984; 37: 367. | en_US |
dc.identifier.citedreference | Vennegoor C, Calafat J, Hageman P et al. Biochemical characterization and cellular localization of a formalin-resistant melanoma-associated antigen reacting with monoclonal antibody NK1-C3. Int J Cancer 1985; 35: 287. | en_US |
dc.identifier.citedreference | Gatter KC, Ralfkiaer E, Skinner J et al. An immunocytochemical study of malignant melanoma and its differential diagnosis from other malignant tumours. J Clin Pathol 1985; 38: 1353. | en_US |
dc.identifier.citedreference | Mahalingam M, LoPiccolo D, Byers HR. Expression of PGP9. 5 in granular cell nerve sheath tumors: an immunohistochemical study of six cases. J Cutan Pathol 2001; 28: 282. | en_US |
dc.identifier.citedreference | Zelger BW, Zelger BG, Steiner H, Ofner D. Aneurysmal and hemangiopericytoma-like fibrous histiocytoma. J Clin Pathol 1996; 49: 313. | en_US |
dc.identifier.citedreference | Zelger BG, Sidoroff A, Zelger B. Combined dermatofibroma: coexistence of two or more variant patterns in a single lesion. Histopathology 2000; 36: 529. | en_US |
dc.identifier.citedreference | Rode J, Dhillon AP, Doran JF, Jackson P, Thompson RJ. PGP. 9.5–a new marker for human neuroendocrine tumors. Histopathology 1985; 9: 147. | en_US |
dc.identifier.citedreference | Thompson RJ, Doran JF, Jackson P, Dhillon AP, Rode J. PGP. 9.5–a new marker for vertebrate neurons and neuroendocrine cells. Brain Res 1983; 278: 224. | en_US |
dc.identifier.citedreference | Fullen DR, Reed JA, Finnerty B, McNutt NS. S100A6 expression in fibrohistiocytic lesions. J Cutan Pathol 2001; 28: 229. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.